硫化氢与急性心肌梗死疗效及再灌注损伤的关系
|
摘要
目的:探讨硫化氢与急性心肌梗死疗效及再灌注损伤的关系。方法:将2017年9月—2018年8月本院接收的急性心肌梗死患者100例作为观察组,将冠脉造影正常者100例设为对照组。测定硫化氢含量,将两组的硫化氢含量进行比对。结果:观察组的硫化氢含量为(28.89±3.76)μmol/L,低于对照组的(52.69±1.47)μmol/L,差异有统计学意义(P<0.05),且不同疗效组别对比硫化氢含量,差异均有统计学意义(P<0.05);观察组患者溶栓治疗后2、4、6、12 h的硫化氢含量均低于溶栓治疗前,差异均有统计学意义(P<0.05)。结论:硫化氢含量能够对急性心肌梗死的病情严重程度以及临床疗效进行判断,同再灌注损伤存在一定的相关性。
Objective:To investigate the relationship between hydrogen sulfide and acute myocardial infarction(AMI)and reperfusion injury.Method:From September 2017 to August 2018,100 patients with acute myocardial infarction received by our hospital were selected as observation group and 100 patients with normal coronary angiography as control group.The content of hydrogen sulfide was determined and compared between the two groups.Result:The content of hydrogen sulfide in the observation group was(28.89±3.76)μmol/L,lower than(52.69±1.47)μmol/L in the control group,the difference was statistically significant(P<0.05).In addition,the content of hydrogen sulfide in different treatment groups were compared,the differences were statistically significant(P<0.05),At 2,4,6 and 12 h after thrombolysis,the content of hydrogen sulfide in the observation group was lower than that before thrombolysis,the differences were statistically significant(P<0.05).Conclusion:The content of hydrogen sulfide can judge the severity of acute myocardial infarction and the clinical efficacy,and has a certain correlation with reperfusion injury.
Objective:To investigate the relationship between hydrogen sulfide and acute myocardial infarction(AMI)and reperfusion injury.Method:From September 2017 to August 2018,100 patients with acute myocardial infarction received by our hospital were selected as observation group and 100 patients with normal coronary angiography as control group.The content of hydrogen sulfide was determined and compared between the two groups.Result:The content of hydrogen sulfide in the observation group was(28.89±3.76)μmol/L,lower than(52.69±1.47)μmol/L in the control group,the difference was statistically significant(P<0.05).In addition,the content of hydrogen sulfide in different treatment groups were compared,the differences were statistically significant(P<0.05),At 2,4,6 and 12 h after thrombolysis,the content of hydrogen sulfide in the observation group was lower than that before thrombolysis,the differences were statistically significant(P<0.05).Conclusion:The content of hydrogen sulfide can judge the severity of acute myocardial infarction and the clinical efficacy,and has a certain correlation with reperfusion injury.
引文
[1]宋诗源,郭中霞.重组人脑利钠肽对急性前壁心肌梗死患者PCI术后心肌缺血再灌注损伤的影响[J].医药论坛杂志,2018,39(11):81-82.
[2]张磊,李肖红,张奇洲,等.18F-FDG PET/CT在远隔缺血后适应对急性ST段抬高型心肌梗死患者再灌注损伤影响中的应用[J].新疆医科大学学报,2018,41(11):1355-1358.
[3]孙卫国.依达拉奉对心肌梗死溶栓治疗后再灌注损伤的影响研究[J].海峡药学,2018,30(3):139-140.
[4]李宏伟,张鑫,张小娜.依达拉奉对急性心肌梗死患者CABG术后心肌保护作用及对血清TNF-α、IL-6、NO水平的影响[J].中国循证心血管医学杂志,2018,10(1):33-36,39.
[5]刘婉嫣,马维辉,金永旭,等.温痹愈梗汤治疗寒凝心脉型急性心肌梗死溶栓后再灌注损伤的临床研究[J].四川中医,2018,36(9):61-64.
[6]于晓钧,曾庆允,彭翠翠.法舒地尔联合瑞舒伐他汀钙对急性心肌梗死患者再灌注损伤和疼痛的影响[J].河北医药,2018,40(11):1694-1696,1700.
[7]马军.三七总皂苷改善急性心肌梗死PCI术后心肌缺血再灌注损伤的临床研究[D].武汉:湖北中医药大学,2018.
[8]陈彦豪,赵先英.内源性硫化氢与心血管疾病的研究进展[J].河北医药,2018,40(15):2365-2367.
[9]何博生,曹巧林,雷永革.硫化氢与急性心肌梗死疗效及再灌注损伤关系探究[J].华夏医学,2018,31(2):19-21.
[10]钱玲玲,刘晓宇,王如兴.硫化氢对常见心血管疾病的保护作用及其机制[J].临床心血管病杂志,2015,31(10):1040-1043.
[11]赵强,贺艳,李国庆,等.急性ST段抬高型心肌梗死患者血浆硫化氢及白细胞介素-6与冠状动脉病变程度关系[J].中华实用诊断与治疗杂志,2015,29(7):684-686.
[12]崔璐璐,聂俊军.尿激酶溶栓联合自拟养心通痹汤治疗急性心肌梗死后缺血再灌注损伤[J].吉林中医药,2017,37(11):1099-1103.
[13]陆琦,崔翰斌.硫化氢和心肌缺血再灌注损伤[J].临床心血管病杂志,2016,32(2):112-115.
[14]杨洁琼,胡明珠,杜斌,等.AMPK/PGC-1α信号通路在硫化氢抗心肌缺血/再灌注损伤中的作用[J].中国药理学通报,2015,31(7):951-956.
[15]何松坚,吴铿,游琼,等.气体信号分子硫化氢对冠心病的保护作用机制及相关性研究[J].中西医结合心脑血管病杂志,2015,13(3):298-301.
[16]黄艳妮,赵祥祥,张亚利,等.硫化氢对心肌缺血/再灌注损伤炎症因子的影响[J].中国循证心血管医学杂志,2017,9(11):1372-1374,1377.
[17]穆丽娜,刘文丽,王佳丽,等.硫化氢通过Nod2信号通路在肾脏缺血再灌注中保护作用的研究[J].中国药物与临床,2017,17(11):1576-1579.
[18]黄坦,黄书岚,陈谦学.硫化氢保护脑缺血再灌注损伤的研究进展[J].中国临床神经外科杂志,2016,21(10):652-654.
[19]兰丽,吉敬,季晖.硫化氢对抗脑缺血再灌注损伤的机制研究进展[J].药学进展,2016,40(4):293-298.
[20]覃志成,刘文丽,李光远,等.硫化氢通过抑制氧化应激减轻肾脏缺血再灌注损伤[J].中华肾脏病杂志,2016,32(2):138-142.
[21]马宪鲁,张申,郑宝石,等.内源性硫化氢在心肌缺血再灌注损伤后心肌保护作用的研究进展[J].现代预防医学,2017,44(9):142-145.
[2]张磊,李肖红,张奇洲,等.18F-FDG PET/CT在远隔缺血后适应对急性ST段抬高型心肌梗死患者再灌注损伤影响中的应用[J].新疆医科大学学报,2018,41(11):1355-1358.
[3]孙卫国.依达拉奉对心肌梗死溶栓治疗后再灌注损伤的影响研究[J].海峡药学,2018,30(3):139-140.
[4]李宏伟,张鑫,张小娜.依达拉奉对急性心肌梗死患者CABG术后心肌保护作用及对血清TNF-α、IL-6、NO水平的影响[J].中国循证心血管医学杂志,2018,10(1):33-36,39.
[5]刘婉嫣,马维辉,金永旭,等.温痹愈梗汤治疗寒凝心脉型急性心肌梗死溶栓后再灌注损伤的临床研究[J].四川中医,2018,36(9):61-64.
[6]于晓钧,曾庆允,彭翠翠.法舒地尔联合瑞舒伐他汀钙对急性心肌梗死患者再灌注损伤和疼痛的影响[J].河北医药,2018,40(11):1694-1696,1700.
[7]马军.三七总皂苷改善急性心肌梗死PCI术后心肌缺血再灌注损伤的临床研究[D].武汉:湖北中医药大学,2018.
[8]陈彦豪,赵先英.内源性硫化氢与心血管疾病的研究进展[J].河北医药,2018,40(15):2365-2367.
[9]何博生,曹巧林,雷永革.硫化氢与急性心肌梗死疗效及再灌注损伤关系探究[J].华夏医学,2018,31(2):19-21.
[10]钱玲玲,刘晓宇,王如兴.硫化氢对常见心血管疾病的保护作用及其机制[J].临床心血管病杂志,2015,31(10):1040-1043.
[11]赵强,贺艳,李国庆,等.急性ST段抬高型心肌梗死患者血浆硫化氢及白细胞介素-6与冠状动脉病变程度关系[J].中华实用诊断与治疗杂志,2015,29(7):684-686.
[12]崔璐璐,聂俊军.尿激酶溶栓联合自拟养心通痹汤治疗急性心肌梗死后缺血再灌注损伤[J].吉林中医药,2017,37(11):1099-1103.
[13]陆琦,崔翰斌.硫化氢和心肌缺血再灌注损伤[J].临床心血管病杂志,2016,32(2):112-115.
[14]杨洁琼,胡明珠,杜斌,等.AMPK/PGC-1α信号通路在硫化氢抗心肌缺血/再灌注损伤中的作用[J].中国药理学通报,2015,31(7):951-956.
[15]何松坚,吴铿,游琼,等.气体信号分子硫化氢对冠心病的保护作用机制及相关性研究[J].中西医结合心脑血管病杂志,2015,13(3):298-301.
[16]黄艳妮,赵祥祥,张亚利,等.硫化氢对心肌缺血/再灌注损伤炎症因子的影响[J].中国循证心血管医学杂志,2017,9(11):1372-1374,1377.
[17]穆丽娜,刘文丽,王佳丽,等.硫化氢通过Nod2信号通路在肾脏缺血再灌注中保护作用的研究[J].中国药物与临床,2017,17(11):1576-1579.
[18]黄坦,黄书岚,陈谦学.硫化氢保护脑缺血再灌注损伤的研究进展[J].中国临床神经外科杂志,2016,21(10):652-654.
[19]兰丽,吉敬,季晖.硫化氢对抗脑缺血再灌注损伤的机制研究进展[J].药学进展,2016,40(4):293-298.
[20]覃志成,刘文丽,李光远,等.硫化氢通过抑制氧化应激减轻肾脏缺血再灌注损伤[J].中华肾脏病杂志,2016,32(2):138-142.
[21]马宪鲁,张申,郑宝石,等.内源性硫化氢在心肌缺血再灌注损伤后心肌保护作用的研究进展[J].现代预防医学,2017,44(9):142-145.